MedTrace Logo

Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock

NCT04917497 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2021-06-08

No results posted yet for this study

Summary

To determine whether Levosimendan infusion in patients with cardiogenic shock and cardiorenal syndrome refractory to standard inotropic therapy, improves hemodynamics and renal function, whilst being safe.

Conditions

  • Cardiogenic Shock
  • Cardiorenal Syndrome
  • Acute Kidney Failure

Interventions

DRUG

Levosimendan

Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Marco Maggiorini · Medizinische Intensivstation D-HOER 27, UniversitatsSpital Zürich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-04-30
Completion
2014-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04917497 on ClinicalTrials.gov